Provan et al. large scandinavian registry study: 🫁ILD risk in RA & PsA initiating b/tsDMARDs HR ILD RA=10 HR ILD PsA=5 No increase risk w/ MTX and b/tsDMARDs but RA HR ILD 1.7 RTX vs. ETA: confounding by indication? https://t.co/CF1ysNkQxU OP0006 #EULAR23 @Rheumnow https://t.co/DgDE1uFeUs

• EULAR Abstract Archive

Data from combined big Scandinavian population registries looking at both RA and PsA, ILD development, & MTX exposure Here’s the ILD risk for methotrexate. Can we stop this MTX misinformation? No more besmirching a really useful drug for our patients #EULAR2023 OP0006 @RheumNow https://t.co/7swqAYchDC

Interstitial lung disease in RA and PSA in b/tsDMARD treated patients with MTX - there is no increased risk of developing ILD above the background risk of RA and PsA vs general population Sella Aarrestad Provan Abst#OP0006 @RheumNow https://t.co/yJsrmraeZ5

Comorbidities and metabolic burden in PsA: -Occur EARLY -Early PsA pts > multiple comorbidities & > CV morbidity vs. age-matched early RA pts Independent of BMI & obesity Time to address these as part of dis pathogenesis in PsA https://t.co/qOiGHn2eZT OP0066 #EULAR23 @Rheumnow https://t.co/lK7MbeMybO

• EULAR Abstract Archive